Please login to the form below

Not currently logged in
Email:
Password:

Warner Chilcott buy P&G's pharma business

Warner Chilcott, the speciality pharmaceuticals company, is to acquire Proctor & Gamble's portfolio of branded pharmaceutical products

Warner Chilcott, the speciality pharmaceuticals company, is to acquire Proctor & Gamble's portfolio of branded pharmaceutical products.

The porfolio of products involved in the acquisition includes Asacol HD (mesalamine), Actone (risedronate sodium) and the co-promotion rights to Enablex (darifenacin), as well as Proctor & Gamble's (P&G) prescription drug product pipeline and manufacturing facilities in Puerto Rico and Germany. Of the 2,300 employees at P&G's pharmaceuticals business, the majority are expected to transfer to Warner Chilcott.

The transaction – for $3.1bn – is likely to close by the end of 2009, pending necessary regulatory approvals. 

Said Roger Boissonneault, president and chief executive officer of Warner Chilcott: "The acquisition transforms Warner Childcott into a global pharmaceutical company, expands our presence in women's healthcare, establishes us in the urology market in advance of the anticipated launch of our erectile dysfunction treatments, and adds gastroenterology therapies to our product portfolio."

P&G said that it believes Warner Chilcott will be a strong investor in P&G's pharmaceutical assets, brands and capabilities and that the move will enable them to "focus singularly on winning in consumer health care".

24th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics